Through the exploration of 12 continuing bonds expressions (CBE), this current study investigated the grief reaction and continuing impact of the death of a pet. Thirty-three individuals were interviewed to determine the degree of connection maintained with the deceased pet and how that affects their coping. Findings emphasize that the majority of respondents frequently maintain ongoing meaningful ties with their deceased pet through the use of CBE such as fond memories, rituals, dreams. The findings suggest that it is not the number of CBE but the degree of adaptability that is significant. The importance of recognizing the unique, total experience of those grieving the death of a pet is addressed. Implications for those working with and supporting those in grief are included. Future directions for research are described.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2190/om.64.4.d | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trial.
EClinicalMedicine
January 2025
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Background: The absolute overall survival (OS) improvement with preoperative chemotherapy or chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC) patients is controversial and unsatisfactory. We designed this trial to explore the efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB NSCLC to facilitate further optimization of this therapeutic strategy.
Methods: Patients diagnosed with stage IIIB NSCLC through invasive staging approaches and/or PET/CT scans and evaluated as having a high probability of radical resection of the primary lesion and metastatic lymph nodes with clear pathological margins by a multidisciplinary team were enrolled in this open-label, single-arm, phase II trial at a single centre in China.
A mitochondrial targeted fluorescent probe for imaging nitroreductase activity and photodynamic therapy in tumor cells.
Talanta
December 2024
Department of Hepato-Pancreato-Biliary Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, 315211, China; Health Science Center, Ningbo University, Ningbo, Zhejiang, 315211, China. Electronic address:
The hypoxic environment in tumors is closely linked to tumor structure, function, dissemination, invasion, metastasis, and drug resistance. Nitroreductase (NTR) is often recognized as a biomarker to evaluate the hypoxia degree for tumor cells. Traditional detection methods such as PET, MRI and multispectral photoacoustic tomography have limitations.
View Article and Find Full Text PDFBreast incidentaloma: Cardiac PET readers beware.
Radiol Case Rep
February 2025
Mayo Clinic Florida, Department of Radiology, Division of Breast Imaging, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.
Breast cancer remains one of the most common causes of cancer and cancer-related death in women. With increases in medical imaging utilization, incidentally detected cancer has become more prevalent. Specifically, breast cancer can be incidentally detected on nuclear cardiac imaging scans due to its high metabolic activity and because the tumor may fall within the field of view during these studies.
View Article and Find Full Text PDFDownregulation of tRNA methyltransferase FTSJ1 by PM2.5 promotes glycolysis and malignancy of NSCLC via facilitating PGK1 expression and translation.
Cell Death Dis
December 2024
School of Public Health, Shenzhen University Medical School, 1066 Xueyuan Ave, Shenzhen, 518055, China.
Fine particulate matter (PM2.5) exposure has been associated with increased incidence and mortality of lung cancer. However, the molecular mechanisms underlying PM2.
View Article and Find Full Text PDFImaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer.
Proc Natl Acad Sci U S A
December 2024
Laboratory of Myeloid Cell Immunology, Vlaams Instituut voor Biotechnologie Center for Inflammation Research, Brussels 1050, Belgium.
Article Synopsis
- Immunotherapies are effective for immune-related diseases like cancer, but patient responses vary, making personalization of treatments essential.
- A novel nanobody-based immunotracer targeting CD163 was developed, which specifically binds to CD163 on macrophages without activating unwanted immune responses.
- This tracer enables noninvasive imaging that distinguishes immunotherapy responders from nonresponders by visualizing differences in CD163 macrophage distribution in tumors, aiding in predicting and monitoring treatment success.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!